1. Home
  2. FABC vs LPCN Comparison

FABC vs LPCN Comparison

Compare FABC & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fabric.AI Inc. Common Stock

FABC

Fabric.AI Inc. Common Stock

N/A

Current Price

$2.43

Market Cap

19.9M

ML Signal

N/A

Logo Lipocine Inc.

LPCN

Lipocine Inc.

N/A

Current Price

$2.27

Market Cap

20.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FABC
LPCN
Founded
N/A
1997
Country
United States
United States
Employees
108
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.9M
20.0M
IPO Year
1999
2011

Fundamental Metrics

Financial Performance
Metric
FABC
LPCN
Price
$2.43
$2.27
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
164.8K
27.8K
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,579,745.00
$1,976,677.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$92.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$1.81
52 Week High
$4.57
$12.37

Technical Indicators

Market Signals
Indicator
FABC
LPCN
Relative Strength Index (RSI) 39.22 53.45
Support Level N/A $2.16
Resistance Level $2.98 $2.30
Average True Range (ATR) 0.17 0.11
MACD -0.03 0.02
Stochastic Oscillator 11.82 48.77

Price Performance

Historical Comparison
FABC
LPCN

About FABC Fabric.AI Inc. Common Stock

Fabric.AI Inc is an infrastructure company building a suite of fabless semiconductor technologies to power AI factories - smart data centers optimized for producing intelligence at scale. The company's innovations include MicroLED-based optical interconnects and other system-critical technologies that enable faster, more efficient, and more scalable AI workloads. Its mission is to transform data centers into unified production systems for artificial intelligence.

About LPCN Lipocine Inc.

Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.

Share on Social Networks: